Argos Therapeutics, Inc. (NASDAQ:ARGS) reports 4Q17 earnings results; Topline Surge; Tops Estimate

Argos Therapeutics, Inc. (NASDAQ:ARGS) reported net loss for the fourth quarter of $ 1.89 million or $ 0.38 per share, compared to loss $ 15.35 million or $ 7.45 per share for the year-ago quarter.

The Durham, North Carolina based company recorded revenue for fourth quarter rose to $ 1.67 million from $ 0.16 million in the same quarter last year.

Analysts polled by Thomson Reuters expected ARGS to report loss of $ 1.4 per share on revenue of $ 0.05 million for the fourth quarter.

Jeff Abbey, CEO, stated, Although we faced a very challenging 2017, we have been able to continue the Phase 3 ADAPT clinical trial of Rocapuldencel-T for the treatment of metastatic renal cell carcinoma, and look forward to the next interim data analysis, which we expect to occur during the second quarter of 2018.

Be the first to comment

Leave a Reply